BridgeMD
Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
EU CTIS ID: 2025-522556-10-01
What this study is testing
To evaluate the efficacy of Tildrakizumab on the ophthalmological sequelae of Lyell syndrome.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults (≥18 years old)
- Non-pregnant and not breastfeeding (if female)
- Presenting with ocular sequelae of Lyell Syndrome
- Able to provide informed consent
- Covered by a social security scheme.
- Patients with a history of SJS/TEN with persistent ocular symptoms or signs compatible with chronic ocular surface inflammation.
You likely can't join if
- Pregnant or breastfeeding woman
- <18 years old
- Receipt of a live attenuated vaccine within 4 weeks prior to inclusion and/or need for a live attenuated vaccine during the study or within 17 weeks after the last dose of Tildrakizumab
- Known hypersensitivity to tildrakizumab
- Patients with a chronic, recurrent, or recent serious infection, or with any suspected clinically relevant active infection
- Active infectious keratitis (bacterial, viral, fungal)
See the full eligibility criteria
- Adults (≥18 years old)
- Non-pregnant and not breastfeeding (if female)
- Presenting with ocular sequelae of Lyell Syndrome
- Able to provide informed consent
- Covered by a social security scheme.
- Patients with a history of SJS/TEN with persistent ocular symptoms or signs compatible with chronic ocular surface inflammation.
- Visual acuity allowing assessment procedures.
- Clinical stability allowing safe ocular examination
- Pregnant or breastfeeding woman
- <18 years old
- Receipt of a live attenuated vaccine within 4 weeks prior to inclusion and/or need for a live attenuated vaccine during the study or within 17 weeks after the last dose of Tildrakizumab
- Known hypersensitivity to tildrakizumab
- Patients with a chronic, recurrent, or recent serious infection, or with any suspected clinically relevant active infection
- Active infectious keratitis (bacterial, viral, fungal)
- Corneal ulcer threatening perforation
- Severe non-SJS/TEN–related ocular diseases (e.g., advanced glaucoma, retinal disease).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.